{
    "clinical_study": {
        "@rank": "107790", 
        "brief_summary": {
            "textblock": "To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides\n      in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii."
        }, 
        "brief_title": "Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse", 
        "condition": [
            "Toxoplasmosis, Cerebral", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Encephalitis", 
                "Toxoplasmosis", 
                "Toxoplasmosis, Cerebral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions are excluded:\n\n          -  Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal\n             meningitis) or other conditions (brain abscess) which would make treatment results\n             difficult to interpret due to concurrent infection, disease, or therapy.\n\n        Patients with other opportunistic infections or brain diseases are excluded.\n\n        Patients with AIDS and cerebral toxoplasmosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002064", 
            "org_study_id": "021A"
        }, 
        "intervention": [
            {
                "intervention_name": "Pyrimethamine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Clindamycin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clindamycin", 
                "Clindamycin-2-phosphate", 
                "Pyrimethamine"
            ]
        }, 
        "keyword": [
            "Sulfonamides", 
            "Toxoplasmosis", 
            "AIDS-Related Opportunistic Infections", 
            "Pyrimethamine", 
            "Drug Therapy, Combination", 
            "Encephalitis", 
            "Acquired Immunodeficiency Syndrome", 
            "Clindamycin"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94301"
                }, 
                "name": "Palo Alto Med Foundation"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002064"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Palo Alto Medical Foundation", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1989"
    }, 
    "geocoordinates": {
        "Palo Alto Med Foundation": "37.442 -122.143"
    }
}